Frontotemporal lobar degeneration with tau pathology (FTLD-tau) encompasses a heterogeneous group of neurodegenerative diseases that share tau protein aggregation as a central pathogenic mechanism. Despite sharing this common endpoint, FTLD-tau subtypes differ markedly in their molecular signatures, histological lesion morphology, cellular distribution, clinical presentation, and genetic architecture. This page provides a systematic comparison of the major FTLD-tau subtypes: Pick's disease (3R), corticobasal degeneration (4R), progressive supranuclear palsy (4R), argyrophilic grain disease (4R), and globular glial tauopathy (4R). [1] [2]
The MAPT gene on chromosome 17q21.31 encodes the microtubule-associated protein tau (MAPT). Alternative splicing of exons 2, 3, and 10 produces six isoforms in the adult human brain, categorized by the presence of three (3R) or four (4R) microtubule-binding repeat domains. This fundamental molecular distinction divides FTLD-tau into 3R-predominant and 4R-predominant subtypes, each with distinct pathobiology. [3] [@araki2021]
The human tau gene contains 16 exons, with exons 2, 3, and 10 subject to alternative splicing. Inclusion of exon 10 adds a fourth microtubule-binding repeat (R1-R4), producing 4R isoforms; exclusion produces 3R isoforms (lacking the N-terminal portion of R2). In the normal adult human brain, 3R and 4R tau isoforms are present in approximately equal proportions. [4] [5]
The microtubule-binding repeat domain (R1-R4) is the primary driver of tau aggregation. The hexapeptide motifs306-VQIVYK-311 and378-VQIVTK-383 within the repeat domain form the β-strand core of tau fibrils. In 4R tauopathies, inclusion of the R2 domain (encoded by exon 10) confers enhanced aggregation propensity and altered filament morphology. [6]
| Property | 3R Tau | 4R Tau |
|---|---|---|
| Microtubule binding affinity | Moderate | Higher (due to extra R2 repeat) |
| Aggregation propensity | Lower baseline | Higher baseline |
| Filament structure | Distinct folds (Pick-type) | Distinct folds (PSP/CBD/AGD-type) |
| Normal brain ratio | ~50% of total tau | ~50% of total tau |
| Disease association | Pick's disease (primary) | PSP, CBD, AGD, GGT |
| Genetic risk | MAPT mutations affecting exon 10 splicing | H1 haplotype (PSP, CBD), MAPT missense mutations |
MAPT mutations in FTLD-tau fall into two broad categories: splicing mutations that disrupt the 3R/4R balance (primarily affecting exon 10), and missense mutations within the microtubule-binding repeats that impair microtubule binding or promote aggregation. Splicing mutations typically produce 4R tauopathies (increased exon 10 inclusion), while missense mutations can produce either 3R or 4R pathology depending on their location. [7]
The H1 haplotype of MAPT (present in >95% of sporadic PSP cases) is the major genetic risk factor for sporadic 4R tauopathies. The H2 haplotype appears protective. These haplotypes influence MAPT transcription, splicing, and possibly the efficiency of tau mRNA degradation. [2:1]
| Feature | Pick's Disease (PiD) | Corticobasal Degeneration (CBD) | Progressive Supranuclear Palsy (PSP) | Argyrophilic Grain Disease (AGD) | Globular Glial Tauopathy (GGT) |
|---|---|---|---|---|---|
| Tau isoform | 3R predominant | 4R predominant | 4R predominant | 4R predominant | 4R predominant |
| Primary lesion | Pick bodies (neurons) | Astrocytic plaques (astrocytes) | Tufted astrocytes (astrocytes) | Argyrophilic grains (neurons/glia) | Globular oligodendroglial inclusions (GOIs) |
| Key histological features | Pick bodies, ballooned neurons, cortical blindness | Asymmetric cortical atrophy, astrocytic plaques, neuronal loss | Tufted astrocytes, coiled bodies, NFT in brainstem | Argyrophilic grains, pretangle pathology, enlarged neurons | Globular inclusions in oligodendrocytes (GOIs) and astrocytes (GAIs) |
| Cellular distribution | Neurons > glia | Astrocytes prominent, neurons, oligodendrocytes | Astrocytes, neurons, oligodendrocytes | Neurons and glia | Oligodendrocytes (GOIs) and astrocytes (GAIs) |
| Filament structure (cryo-EM) | Three-helix fold, distinct from AD | Two-protofilament fold, distinct from PSP/AD | Two-protofilament fold, distinct from CBD/AD | Two-protofilament fold, distinct from CBD/AD | Distinct from PSP and CBD |
| Typical onset age | 40-65 years | 50-70 years | 55-70 years | 60-80 years | 50-75 years |
| Clinical phenotype | FTD (behavioral/language), rapid progression | CBS, asymmetric rigidity, apraxia, alien limb | PSP syndromes (vertical gaze palsy, falls, parkinsonism) | Late-onset dementia with memory/behavioral changes | FTD-ALS spectrum, bvFTD, motor neuron disease |
| Motor involvement | Variable | Prominent (parkinsonism, dystonia, myoclonus) | Prominent (axial rigidity, gaze palsy) | Mild | Often prominent (ALS/PLS features) |
| MAPT mutations | Some familial cases | Rare (usually 4R) | H1 haplotype strong risk; rare mutations | H1 haplotype risk | Rare (4R) |
| Other genetic risk | Unknown | GRN, TMEM106B | H1/H1 haplotype | Unknown | Unknown |
| Diagnostic biomarkers | CSF p-tau181, tau PET | NfL, tau PET (limited) | NfL, CSF p-tau231, tau PET | Limited | Limited |
Pick's disease is the prototypical 3R tauopathy, characterized neuropathologically by the presence of Pick bodies — round to oval, argyrophilic intracytoplasmic inclusions composed predominantly of 3R tau isoforms. [8] Cryo-EM studies have revealed that Pick body filaments adopt a three-helix fold distinct from the two-protofilament folds observed in Alzheimer's disease and 4R tauopathies. [9]
Pick bodies are composed of hyperphosphorylated 3R tau arranged in a paired helical filament-like structure, but structurally distinct from the classic paired helical filaments of AD. The inclusions are tau-positive, ubiquitin-positive, and p62-positive, with variable TDP-43 co-pathology in some cases. [2:2]
The classic triads of Pick's disease include: [4:1]
Pick's disease typically presents with the behavioral variant of frontotemporal dementia (bvFTD) or primary progressive aphasia variants. The clinical phenotype reflects frontotemporal neurodegeneration: [1:1]
Corticobasal degeneration is a 4R tauopathy with a characteristic asymmetric distribution of pathology. Cryo-EM studies have shown that CBD filaments adopt a two-protofilament fold that is distinct from both Alzheimer's disease and progressive supranuclear palsy filaments, despite both being 4R tauopathies. [6:1] [10]
The 4R tau in CBD is hyperphosphorylated at multiple epitopes (AT8, AT100, PHF-1) and forms distinct ultrastructural filaments that differ in their protofilament packing from PSP. This structural distinction may explain the clinical and pathological heterogeneity between these disorders. [9:1]
The characteristic lesions of CBD include: [11] [12]
Astrocytic plaques: The pathognomonic lesion of CBD — annular or wreath-like tau-positive inclusions in astrocytic processes. Unlike the tufted astrocytes of PSP, astrocytic plaques form a diffuse, peripheral pattern around the astrocyte cell body, best visualized with Gallyas silver stain and 4R tau immunohistochemistry.
Neuronal tau pathology: Oligodendroglial coiled bodies (crescentic inclusions in oligodendrocyte nuclei), pretangle tau pathology in neurons, and neurofibrillary tangles similar to PSP but with different distribution.
Asymmetric cortical atrophy: Particularly affecting frontoparietal regions, with neuronal loss, gliosis, and spongiosis. The motor cortex and basal ganglia (especially the substantia nigra) are consistently involved.
The classic clinical presentation of corticobasal degeneration is corticobasal syndrome (CBS): [12:1]
Progressive supranuclear palsy is the most common 4R tauopathy and the most frequent neurodegenerative cause of atypical parkinsonism. The H1 MAPT haplotype is present in over 95% of sporadic cases, making it the strongest genetic risk factor in neurodegeneration. [13] [14]
Cryo-EM studies have revealed that PSP tau filaments adopt a two-protofilament fold that is distinct from CBD filaments, despite both being 4R tauopathies with similar ultrastructural features under conventional EM. The structural differences in protofilament packing correlate with the distinct clinical phenotypes and neuropathological lesion types of these two disorders. [9:2]
The hallmark lesions of PSP include: [13:1]
Tufted astrocytes: The most characteristic lesion, with tau-immunoreactive processes arranged in a tufted or bushy pattern around the astrocyte cell body. These are best visualized with 4R tau immunohistochemistry and are found predominantly in the basal ganglia, brainstem, and motor cortex. Unlike astrocytic plaques (CBD), tufted astrocytes have a compact, perinuclear distribution.
Coiled bodies: Oligodendroglial inclusions with a crescent or coiled morphology, found in the white matter and subcortical structures. These are also 4R tau-positive and distinguish PSP from AD.
Neurofibrillary tangles:Globular or flame-shaped intraneuronal inclusions in the brainstem nuclei (particularly the substantia nigra pars compacta, locus coeruleus), basal ganglia, dentate nucleus of the cerebellum, and cortex.
Glial tau pathology: Thorn-shaped astrocytes in the motor cortex and astrocytic plaques in the subthalamic nucleus and other regions.
The classic presentation is the Richardson syndrome (PSP-Richardson syndrome): [14:1]
Multiple clinical variants of PSP are now recognized, including PSP-parkinsonism (PSP-P), PSP-pure akinesia with gait freezing (PSP-PAGF), PSP-corticobasal syndrome (PSP-CBS), and others — each with different clinicopathological correlations.
Argyrophilic grain disease is a 4R tauopathy characterized by the presence of argyrophilic grains — spindle-shaped, argyrophilic inclusions in neuronal processes and dendrites. AGD is increasingly recognized as a common contributor to late-onset dementia, often co-existing with AD-type amyloid pathology. [15]
Like CBD and PSP, AGD tau filaments adopt a two-protofilament fold, but structural studies suggest subtle differences in protofilament packing that may account for the distinct grain-like morphology. [9:3]
The characteristic lesions of AGD include: [15:1]
Argyrophilic grains: Spindle-shaped, silver-staining inclusions distributed in the hippocampal formation (CA1, subiculum), entorhinal cortex, and limbic structures. Grains are primarily located in neuronal dendrites and represent "thread-like" processes with tau pathology.
Pretangle tau pathology: Diffuse, granular cytoplasmic tau staining in neurons (especially in the limbic system) without well-formed NFT.
Enlarged neurons: Ballooned neurons with phosphorylated tau in the amygdala and other limbic structures, resembling Pick cells but without Pick bodies.
Oligodendroglial coiled bodies: Similar to those seen in PSP and CBD, but less prominent.
AGD typically presents as a late-onset dementia with prominent behavioral and memory features: [15:2] [16]
Globular glial tauopathy is a rare 4R tauopathy distinguished by globular inclusions in both oligodendrocytes and astrocytes, with oligodendroglial pathology predominating. The condition was unified under the GGT nomenclature in 2013 and represents a distinct entity within the 4R tauopathy spectrum. [17]
The globularity of the inclusions (spherical, well-circumscribed, displacing the nucleus peripherally) distinguishes them from the crescent-shaped coiled bodies of PSP and the annular astrocytic plaques of CBD. [18]
Three neuropathological subtypes are recognized based on regional distribution: [17:1]
Type I — Frontotemporal pattern: Predominant frontotemporal cortical and white matter involvement with globular oligodendroglial inclusions (GOIs) as the dominant lesion. Clinically presents as bvFTD with behavioral changes and executive dysfunction.
Type II — Motor-predominant pattern: Severe involvement of motor cortex, corticospinal tracts, and spinal cord motor neurons, with both GOIs and globular astroglial inclusions (GAIs). Clinically resembles ALS or primary lateral sclerosis with upper and lower motor neuron signs.
Type III — Combined pattern: Mixed frontotemporal and motor system involvement, clinically presenting as FTD-ALS spectrum with both cognitive impairment and motor neuron disease.
The defining lesions are: [18:1]
GGT typically presents with: [18:2] [19]
Cryo-electron microscopy has revolutionized the understanding of tauopathies by revealing distinct filament folds across diseases. These structural differences provide a molecular basis for the observed pathological and clinical heterogeneity. [6:2] [9:4]
| Tauopathy | Filament Fold | Protofilament Architecture | C-Terminal Conformation |
|---|---|---|---|
| Alzheimer's disease | Two-protofilament, helical | Asymmetric, L-shaped | Folded back |
| Pick's disease | Three-helix fold | Novel compact fold | Extended |
| CBD | Two-protofilament | Distinct packing from PSP | Folded back |
| PSP | Two-protofilament | Distinct packing from CBD | Folded back |
| AGD | Two-protofilament | Related to PSP/CBD but distinct | Folded back |
| GGT | Distinct | Different from PSP and CBD | Under characterization |
The structural differences between CBD and PSP filaments — despite both being 4R tauopathies with similar appearance under conventional electron microscopy — explain the distinct histological lesion types (astrocytic plaques vs. tufted astrocytes) and clinical phenotypes. These structural differences also have implications for biomarker development and therapeutic targeting, as conformation-specific antibodies and PET ligands may be able to distinguish between these entities. [9:5]
A distinguishing feature of 4R tauopathies is the prominence of glial tau pathology, which varies in morphology, cellular distribution, and anatomical distribution across subtypes. This represents a key differential feature. [18:3]
| Glial Feature | Pick's Disease | CBD | PSP | AGD | GGT |
|---|---|---|---|---|---|
| Astrocytic tau | Rare | Prominent (plaques) | Prominent (tufted) | Moderate (thorn-shaped) | Moderate (GAIs) |
| Oligodendroglial tau | Rare | Moderate (coiled bodies) | Moderate (coiled bodies) | Moderate (coiled bodies) | Very prominent (GOIs) |
| Astrocyte morphology | Ballooned neurons predominant | Annular/wreath plaques | Tufted perinuclear | Thorn-shaped | Globular spherical |
| Oligodendrocyte morphology | Minimal involvement | Crescents/coiled | Crescents/coiled | Crescents/coiled | Large spherical globules |
| White matter involvement | Mild | Moderate | Moderate | Moderate | Severe |
Despite their clinical and pathological differences, all FTLD-tau subtypes share several core pathogenic mechanisms: [1:2] [16:1]
Tau hyperphosphorylation: Increased activity of kinases (GSK-3β, CDK5, MAPK) and/or decreased activity of phosphatases (PP2A) leads to hyperphosphorylated tau that dissociates from microtubules and becomes available for aggregation.
Tau misfolding and aggregation: Pathological tau adopts a β-sheet-rich conformation that templates the misfolding of normal tau through a prion-like propagation mechanism.
Microtubule destabilization: Loss of functional tau from microtubules leads to impaired axonal transport, synaptic dysfunction, and axonal degeneration.
Neuronal and glial dysfunction: Tau pathology in neurons and glia contributes to neuroinflammation, metabolic impairment, and cell death.
Prion-like propagation: Templated tau aggregation allows pathology to spread along connected brain networks, explaining the progressive nature of these diseases.
| Mechanism | 3R Tauopathies (Pick's) | 4R Tauopathies |
|---|---|---|
| Isoform affected | 3R predominates | 4R predominates |
| Primary cellular target | Neurons | Astrocytes and oligodendrocytes prominent |
| Aggregation propensity | Moderate | High (extra R2 repeat) |
| Filament fold | Three-helix compact | Two-protofilament extended |
| Clinical phenotype | FTD behavioral/language | Parkinsonism (PSP), CBS, dementia |
| H1 haplotype risk | Weaker | Very strong |
| Typical progression | Rapid | Slower, more varied |
The distinct molecular signatures of FTLD-tau subtypes have important implications for therapeutic development. Tau-targeted therapies under investigation include: [5:1]
The structural differences between 3R and 4R tau filaments suggest that some therapeutic agents may be subtype-specific, while others (ASO therapy, general aggregation inhibitors) may be broadly applicable across FTLD-tau subtypes.
Karimov A, et al. Tauopathies: a update on classification, biomarkers and histology. 2022. ↩︎ ↩︎ ↩︎
Dickson DW, et al. Neuropathology of frontotemporal lobar degeneration: new insights into genetic and sporadic forms. Acta Neuropathologica. 2023. ↩︎ ↩︎ ↩︎
Goedert M, et al. Tau filaments in neurodegenerative diseases. Annual Review of Neuroscience. 2017. ↩︎
Goedert M, et al. The neuropathology of frontotemporal dementia. Annals of Neurology. 2003. ↩︎ ↩︎
Bhangare Y, et al. Molecular insights and therapeutic advances for 4R tauopathies. Ageing Research Reviews. 2022. ↩︎ ↩︎
Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer's disease, corticobasal degeneration and Picks disease. Nature. 2017. ↩︎ ↩︎ ↩︎
Schofield E, et al. Tauopathy subtypes: clinical, neuropathological and genetic correlates. Brain. 2012. ↩︎
Sergeant N, et al. Tau isoform pattern and pathological characteristics in Pick's disease. Journal of Pathology. 2005. ↩︎
Baiken Y, et al. Tau cryo-EM structures in FTLD-tau subtypes reveal distinct amyloid folds. Cell. 2024. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Kovacs GG, et al. Neuropathology of corticobasal degeneration. Acta Neuropathologica. 2020. ↩︎
Dickson DW, et al. Astrocytic plaques in corticobasal degeneration. Acta Neuropathologica. 2019. ↩︎
Armstrong MJ, et al. Corticobasal degeneration: one hundred years and counting. Journal of Neuropathology and Experimental Neurology. 2020. ↩︎ ↩︎
Kovacs GG, et al. Neuropathology of progressive supranuclear palsy. Acta Neuropathologica. 2020. ↩︎ ↩︎
Josephs KA, et al. Neuropathologic basis of clinical manifestations in progressive supranuclear palsy. Brain. 2019. ↩︎ ↩︎
Tolnay M, et al. Argyrophilic grain disease: an update. Acta Neuropathologica. 2022. ↩︎ ↩︎ ↩︎
Schweighofer M, et al. Clinical and neuropathological overlap between FTLD-tau subtypes. Neuropathology and Applied Neurobiology. 2023. ↩︎ ↩︎
Ahmed Z, et al. Globular glial tauopathies: a consensus recommendation. Acta Neuropathologica. 2013. ↩︎ ↩︎
Deller T, et al. Glial tauopathies in the human brain. Frontiers in Neurology. 2019. ↩︎ ↩︎ ↩︎ ↩︎
Kovacs GG, et al. Aging and astrocytic tau pathology in human and non-human primate brain. Acta Neuropathologica. 2018. ↩︎